Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions
Status:
Completed
Trial end date:
2002-01-01
Target enrollment:
Participant gender:
Summary
The Purpose of this study os to evaluate the relative bioavailability of the test formulation
of terbinafine tablets with an already marketed reference formulation Lamisil® (Novartis
Pharmaceuticals), under post-prandial conditions in healthy, non-tobacco using male and
female adult subjects.